Immunological Mechanisms in Sepsis Treatment

Sepsis arises from a dysregulated host response to infection, initiating a biphasic immunological cascade. The early phase is typified by an overwhelming pro-inflammatory cytokine surge that, while intended to eradicate pathogens, often precipitates collateral tissue damage and organ dysfunction. This is followed by a compensatory immunosuppressive phase, characterised by lymphocyte apoptosis, exhaustion of innate immune effector cells and expansion of regulatory subsets, which collectively increase susceptibility to secondary infections and impair recovery. Contemporary strategies aim to restore immune homeostasis through selective modulation of cytokine networks, blockade of inhibitory checkpoints and prevention of immune cell death. These include antagonists of immune-inhibitory molecules, agonists to bolster T-cell and macrophage function, and novel natural compounds that attenuate hyperinflammation without provoking excessive immunosuppression. Precision immunophenotyping and biomarker-guided approaches promise to tailor interventions to individual immune trajectories, offering global impact in reducing sepsis mortality and long-term morbidity.

Research from Nature Portfolio

Recent studies have uncovered a subset of regulatory plasma cells expressing PD-L1 that directly suppress T-cell proliferation and interferon-γ production via cell–cell contact and soluble mediators, identifying a potential immune-checkpoint target to reverse sepsis-induced T-cell dysfunction. Work on interleukin-33 reveals its pivotal role in driving long-term immunosuppression: tissue injury-released IL-33 activates innate lymphoid cells and M2 macrophages, promoting regulatory T-cell expansion and IL-10 secretion, thereby sustaining immune paralysis post-sepsis. Foundational research has also characterised small-molecule natural products that inhibit key inflammatory transcription factors, demonstrating attenuation of cytokine release, organ injury markers and mortality in preclinical models, and laying groundwork for immunomodulatory drug development.

Immunological Mechanisms in Sepsis Treatment publication trend

The graph below shows the total number of articles in immunological mechanisms in sepsis treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Checkpoint inhibitor: A molecule that blocks inhibitory signalling pathways in immune cells, enhancing their activity.

Cytokine storm: An excessive release of pro-inflammatory cytokines that can cause tissue injury and organ failure.

Immunopathology: Tissue damage resulting from an aberrant or overactive immune response.

Immunosuppression: A state of reduced immune responsiveness increasing vulnerability to infections.

Regulatory plasma cell: A subset of antibody-secreting cells with immunosuppressive functions mediated by molecules such as PD-L1.

Apoptosis: Programmed cell death characterised by cell shrinkage, DNA fragmentation and membrane blebbing.

References

1. Three-dimensional label-free morphology of CD8 + T cells as a sepsis biomarker. Light: Science & Applications (2023).
2. PD-L1+ plasma cells suppress T lymphocyte responses in patients with sepsis and mouse sepsis models. Nature Communications (2025).
3. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death & Disease (2019).
4. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nature Communications (2017).
5. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response. Scientific Reports (2017).
6. Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge. Scientific Reports (2016).
7. Inflammation and Cell Death of the Innate and Adaptive Immune System during Sepsis. Biomolecules (2021).